Allergan Aesthetics' Carrie Strom on the 'aesthetics generation' and new frontiers for injectables

02/15/24 • 33 min

Botox has dominated the neurotoxin market since its FDA approval for cosmetic use in 2002. However, its iconic status would not be possible without the backing of global company Allergan Aesthetics.

In addition to Botox, Allergan Aesthetics itself a subsidiary of pharmaceutical company AbbVie, which houses aesthetics brands including Juvéderm, SkinVive, Kybella and Coolsculpting, among others. In its full-year 2023 earnings released in February, AbbVie reported that the global net revenue of its aesthetics portfolio was about $5.3 billion, with global Botox Cosmetic's net revenue reaching $2.7 billion and global Juvéderm's net revenue equalling $1.4 billion. Leading this portfolio of aesthetics products, and guiding the future of the aesthetics industry, is Carrie Strom, svp of AbbVie and Global Allergan Aesthetics president.

Strom has kept busy over the last year. In May 2023, Allergan received FDA approval for Skinvive by Juvéderm, and in early Oct. 2023, it became available for patients to receive as a treatment. Skinvive has been available in Europe since 2017 and marketed under the name “Volite.” Plus, the company has driven countless marketing moments, including the first-ever Juvéderm Day in Aug. 2023 and the fifth-annual National Botox Day in Nov. 2023. In addition, Strom has busied herself by shoring up Botox’s status, as competitors, including Jeuveau and long-lasting neurotoxin Daxxify, nip at its heels.

In conversation on the Glossy Beauty podcast, Strom discussed how younger consumers are changing the aesthetics market and how Skinvive can serve as an entry point for new patients, among other topics.

Botox has dominated the neurotoxin market since its FDA approval for cosmetic use in 2002. However, its iconic status would not be possible without the backing of global company Allergan Aesthetics.

Previous Episode

Renée Rouleau on taking on retail partners after 27 years in business

Renée Rouleau, the celebrity esthetician and entrepreneur, opened her first spa and launched her first product in 1996. By 1999, she had become an early entrant in e-commerce.

Today, rather than giving facials, Rouleau is focused on her role of founder and CEO of her brand, which offers a robust assortment of SKUs. Still, she makes time for celebrity clients, which include Lili Reinhart and Demi Lovato. Rouleau is known for her unique approach to categorizing skin — she does so by assigning it to nine types, rather than the traditional three or four.

On this week’s episode of the Glossy Beauty Podcast, Rouleau spoke about how she categorizes skin, how getting a headstart on e-commerce worked to her brand's advantage and why, after 27 years, she's rethinking her DTC sales focus.

Next Episode

CEO Kyle Leahy on what Glossier has in common with Taylor Swift and whether it's reformulated its You fragrance

Kyle Leahy, Glossier's first CEO after its founder Emily Weiss vacated the role in May 2022, has had a busy first year-and-a-half in the job. She brought the brand into wholesale for the first time. brokering its partnership with Sephora, which has been a great success. She's also continued the brand's WNBA partnership, launched its first college tour and increased the cadence of its launches. But perhaps most importantly, she can be credited with the revival of the brand, which, as she said in her 2023 Glossy 50 profile, is a long-haul job: “We genuinely believe we’re on year 10 of building a 100-year brand.”

On this week’s episode of the Glossy Beauty Podcast, Leahy spoke about all of the above, in addition to what the brand did when Reddit leaked its eye cream launch and what Glossier has in common with Taylor Swift. She also addressed social media rumors regarding whether or not the brand had reformulated its bestselling fragrance, Glossier You.

Get more from Glossy with the daily newsletter, sent out each weekday morning. Visit glossy.co/newsletters to sign up.